Rajiv Sarman Shukla
Amministratore Delegato presso CARMELL CORPORATION
Patrimonio netto: 14 M $ in data 31/05/2024
Profilo
Rajiv Sarman Shukla was the founder and had founded Constellation Alpha Capital Corp.
in 2015, where he held the title of Chairman & Chief Executive Officer.
He is currently the Chairman & Chief Executive Officer at Carmell Corp.
and Director at InflammX Therapeutics, Inc. He previously served as the Chief Executive Officer at Reliance Naval & Engineering Ltd.
from 2013 to 2015 and as the Chairman & Chief Executive Officer at Venturcap Financial Group LLC from 2017 to 2019.
Mr. Shukla has also held various director positions at companies such as Alpha Healthcare Acquisition Corp., Alpha Healthcare Acquisition Corp.
III, OcuNexus Therapeutics, Inc., Malladi Drugs & Pharmaceuticals Ltd., Avantor Performance Materials India Ltd., Arch Pharmalabs Ltd., Unimark Remedies Ltd., Avendus Capital Pvt Ltd., Bharat Biotech International Ltd., I-VEN Medi-care India Pvt Ltd., and Swiss Bio Pharma Pvt Ltd.
He was a Senior Director at Pfizer Inc. from 2001 to 2006.
Mr. Shukla's education includes a graduate degree from Harvard University, an undergraduate degree from the Indian Institute of Technology Madras, and an undergraduate degree from Banaras Hindu University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
HUMACYTE, INC.
1.52% | 31/03/2024 | 1 814 789 ( 1.52% ) | 14 M $ | 31/05/2024 |
| 06/06/2024 | 72 103 ( 0.35% ) | 179 536 $ | 31/05/2024 |
Posizioni attive di Rajiv Sarman Shukla
| Società | Posizione | Inizio |
|---|---|---|
| CARMELL CORPORATION | Amministratore Delegato | 31/08/2023 |
InflammX Therapeutics, Inc.
 InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Direttore/Membro del Consiglio | 01/08/2019 |
Precedenti posizioni note di Rajiv Sarman Shukla
| Società | Posizione | Fine |
|---|---|---|
| HUMACYTE, INC. | Direttore/Membro del Consiglio | 11/06/2024 |
Constellation Alpha Capital Corp.
 Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | Amministratore Delegato | 01/08/2019 |
| Venturcap Financial Group LLC | Amministratore Delegato | 01/01/2019 |
| RELE NAVAPAR | Amministratore Delegato | 01/05/2015 |
| PFIZER, INC. | Direttore/Membro del Consiglio | 01/01/2006 |
Formazione di Rajiv Sarman Shukla
| Harvard University | Graduate Degree |
| Indian Institute of Technology Madras | Undergraduate Degree |
| Banaras Hindu University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| RELE NAVAPAR | Producer Manufacturing |
| HUMACYTE, INC. | Health Technology |
| CARMELL CORPORATION | Health Technology |
| Aziende private | 16 |
|---|---|
OcuNexus Therapeutics, Inc.
 OcuNexus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology OcuNexus Therapeutics, Inc. develops and commercializes therapeutic products for wound care and tissue repair. The firm offers Nexagon, an oligonucleotide that downregulates the gap junction in tissue repair. Its Nexagon also reduces lesion spread, swelling, inflammation, scarring, and time to wound closure in various tissue types, including the eye, skin, spinal cord, nerve, and brain. The company was founded in 2005 by David Lawrence Becker, Colin C. Green and Bradford J. Duft and is headquartered in San Diego, CA. | Health Technology |
Morgan Stanley Investment Management Pvt Ltd.
 Morgan Stanley Investment Management Pvt Ltd. Investment Banks/BrokersFinance Morgan Stanley Investment Management Pvt Ltd. (India) (MSIM), founded in 1993, is an asset management subsidiary of Morgan Stanley (NYSE: MS). The firm specializes in managing assets for a range of institutional clients, including endowments, foundations, pension funds, corporations, governments, and high-net worth individuals. The Mumbai office focuses on managing portfolios of Indian securities. MSIM has offices in New York, Philadelphia, Houston, Chicago, London, Tokyo, Amsterdam and Singapore. | Finance |
ICICI Venture Funds Management Co. Ltd.
 ICICI Venture Funds Management Co. Ltd. Investment ManagersFinance ICICI Venture Funds Management Co. Ltd (ICICI) is a Private Equity firm, a subsidiary of ICICI Bank Ltd. founded in 1988. The firm is headquartered in India. | Finance |
Malladi Drugs & Pharmaceuticals Ltd.
 Malladi Drugs & Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Malladi Drugs & Pharmaceuticals Ltd. manufactures active pharmaceutical ingredients. It manufactures Ephedrine and Pseudo-Ephedrine. The firm's products include active pharmaceutical ingredients, intermediates and speciality products,and chiral building blocks and speciality chemicals. Its services include contract manufacturing, custom synthesis and contract research. The company was founded by M. L. N. Satry in 1980 and is headquartered in Chennai, India. | Health Technology |
Avantor Performance Materials India Ltd.
 Avantor Performance Materials India Ltd. Pharmaceuticals: MajorHealth Technology Avantor Performance Materials India Ltd. manufactures and distributes pharmaceutical products. Its products include acids, amino acids, aqueous solutions, biological regents and denaturants. The company was founded by John Townsend Baker in 1904 and is headquartered in Gurgaon, India. | Health Technology |
Arch Pharmalabs Ltd.
 Arch Pharmalabs Ltd. Pharmaceuticals: MajorHealth Technology Arch Pharmalabs Ltd. manufactures and sells pharmaceutical products. Its therapeutic segments include side chains of Semi-Synthetic Isoxazole Penicillins under Antibiotics, Lipid Lowering Agents, Oncology, Anti-Platelet Agents, Anti-Asthmatic, Anti-Retroviral, Decongestant, Anti-Herpes, Anti-Malarial, NSAIDs and Anti-Anginal segments. The company was founded in 1975 and is headquartered in Mumbai, India. | Health Technology |
Unimark Remedies Ltd.
 Unimark Remedies Ltd. Pharmaceuticals: MajorHealth Technology Unimark Remedies Ltd. develops and markets active generic medicines. It specializes in pharmaceutical products for respiratory, cardiovascular, anti-infectives, and central nervous system. The company was founded in 1982 and is headquartered in Mumbai, India. | Health Technology |
Avendus Capital Pvt Ltd.
 Avendus Capital Pvt Ltd. Investment Banks/BrokersFinance Avendus Capital Pvt Ltd. provides financial services. The firm offers financial advisory, mergers and acquisitions, private equity syndication, equity capital markets, structured finance, financial sponsors group, wealth management, alternative asset management, and institutional equities. The company was founded by Ranu Vohra, Gaurav Deepak and Kaushal Aggarwal and is headquartered in Mumbai, India. | Finance |
Bharat Biotech International Ltd.
 Bharat Biotech International Ltd. BiotechnologyHealth Technology Bharat Biotech International Ltd. engages in research and development, manufacturing, marketing and distribution of vaccines and biotherapeutics. It focuses on the development of novel health care solutions for region-specific neglected diseases. The firm offers Revac-B+, REGEN-D, HNVAC, COMVAC5, BIOPOLIO, INDIRAB, Typbar TCV, BIOHIB, JENVAC, ROTAVAC and vaccine candidates against chikungunya, chandipura, HPV and Ebola. The company was founded by Krishna Murthy Ella and Suchitra K. Ella in 1996 and is headquartered in Hyderabad, India.. | Health Technology |
I-VEN Medi-care India Pvt Ltd.
 I-VEN Medi-care India Pvt Ltd. MiscellaneousMiscellaneous I-VEN Medicare India Pvt Ltd. provides investment services in the healthcare sectors. It invests in hospitals and research institutes. The company is headquartered in Bangalore, India. | Miscellaneous |
| Swiss Bio Pharma Pvt Ltd. | |
Constellation Alpha Capital Corp.
Constellation Alpha Capital Corp. Financial ConglomeratesFinance Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL. | Finance |
| Venturcap Financial Group LLC | |
Alpha Healthcare Acquisition Corp.
 Alpha Healthcare Acquisition Corp. Financial ConglomeratesFinance Alpha Healthcare Acquisition Corp. operates as a blank check company, which is formed in order to effect a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination with one or more businesses or entities. The company was founded on July 1, 2020 and is headquartered in New York, NY. | Finance |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | Commercial Services |
Alpha Healthcare Acquisition Corp. III
 Alpha Healthcare Acquisition Corp. III Financial ConglomeratesFinance Alpha Healthcare Acquisition Corp. III is a blank check company, which engages in the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 21, 2021 and is headquartered in New York, NY. | Finance |
- Borsa valori
- Insiders
- Rajiv Sarman Shukla
